Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction
Conditions: Plaque, Atherosclerotic Interventions: Drug: atorvastatin; Procedure: IVUS/OCT; Drug: inclisiran Sponsors: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Improving Cardiovascular Health Risks in Adults With Epilepsy on a Modified Atkins Diet
Conditions: Epilepsy; Dyslipidemia Interventions: Drug: Atorvastatin 10mg; Other: Modification of dietary fat composition Sponsors: Johns Hopkins University; American Heart Association Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction
Conditions: STEMI Interventions: Drug: evolocumab; Drug: Atorvastatin Sponsors: Beijing Luhe Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke
Conditions: Ischemic Stroke Interventions: Drug: Atorvastatin 40 Mg Oral Tablet; Drug: Rosuvastatin 20mg Sponsors: Kafrelsheikh University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Minor Stroke or TIA
Conditions: Ischemic Stroke Interventions: Drug: Atorvastatin 40mg; Drug: Rosuvastatin 20mg Sponsors: Kafrelsheikh University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Clinical effects of atorvastatin combined with conbercept in the treatment of patients with macular edema secondary to retinal vein occlusion and carotid plaque: study protocol for a prospective randomized controlled trial
This study aims to observe the clinical effects of atorvastatin and intravitreal therapy in the treatment of patients with branch or central RVO-ME and coexistent carotid plaques (CP).Methods and analysisA prospective randomized controlled clinical trial will be conducted. Sixty-four patients diagnosed with branch or central RVO-ME and coexistent CP will be enrolled and randomly allocated in a 1:1 ratio to the control and experimental groups. The control group will be treated with intravitreal conbercept monthly for 3 months, followed by monthly evaluation and injection of pro re nata (PRN) for 12 months, while the experim...
Source: Trials - April 8, 2024 Category: Research Source Type: clinical trials
Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study
Conditions: Intracranial Atherosclerosis; Cognitive Impairment; Cerebrovascular Event Interventions: Drug: Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin; Procedure: Endovascular therapy,Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin Sponsors: Anhui Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials
Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma
Conditions: Glioblastoma, IDH-wildtype Interventions: Drug: Atorvastatin 20mg Sponsors: Tianjin Medical University General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials
Novel Approaches for Improving Vascular Function in Veterans With HFpEF
Conditions: HFpEF - Heart Failure With Preserved Ejection Fraction; Inflammation Interventions: Drug: L-Citrulline then Placebo; Drug: Placebo then L-Citrulline; Drug: BH4 then Placebo; Drug: Placebo then BH4; Drug: Atorvastatin then Placebo; Drug: Placebo then Atorvastatin Sponsors: D. Walter Wray; US Department of Veterans Affairs Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Effectiveness of Atorvastatin in Preventing Cerebrovascular Events After Flow Diverter Implantation
Conditions: Efficacy Endpoint: no New Cerebrovascular Adverse Events Within 1 Year; Safety Endpoint: no New Moderate or Serious Adverse Events Within 1 Year; All-cause Mortality Events (Within 1 Year); Incident Ischemic Stroke Events (Within 1 Year); New Hemorrhagic Stroke Events (Within 1 Year); New Stent Thrombosis Events (Within 1 Year); New Symptomatic Stenosis Events (Within 1 Year); Occurrence of In-stent Stenosis 12th ±1 Month Annual Angiographic Follow-up; Degree of In-stent Stenosis (as Measured by WASID Method) at the 12th ±1 Month Annual Angiographic Follow-up; Target Aneurysm Embolization Rate at 12±1 Month ...
Source: ClinicalTrials.gov - March 13, 2024 Category: Research Source Type: clinical trials
ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants
Conditions: Type 2 Diabetes Mellitus Interventions: Drug: ECC5004; Drug: Midazolam; Drug: Rosuvastatin; Drug: Digoxin; Drug: Atorvastatin Sponsors: Eccogene Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight
Conditions: Obesity Interventions: Drug: Cagrilintide; Drug: Semaglutide; Drug: Atorvastatin; Drug: Warfarin Sponsors: Novo Nordisk A/S Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials
Evaluation of the Pharmacokinetics of Microdose Midazolam, Dabigatran, Pitavastatin, Atorvastatin and Rosuvastatin in Diabetic Patients
Conditions: Diabetes Interventions: Drug: The combinations of 10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin were administered to diabetic patients on an empty stomach. Sponsors: Peking University Third Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials
Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins
Conditions: Cardiovascular Diseases; Dyslipidemias; Statin Adverse Reaction; Pharmacogenic Myopathy Interventions: Other: Preemptive pharmacogenetic atorvastatin dose based on CPIC guidelines; Other: Preemptive pharmacogenetic simvastatin dose based on CPIC guidelines; Other: Preemptive pharmacogenetic pitavastatin dose based on CPIC guidelines; Other: Preemptive pharmacogenetic rosuvastatin dose based on CPIC guidelines; Other: Preemptive pharmacogenetic pravastatin dose based on CPIC guidelines; Other: Preemptive pharmacogenetic lovastatin dose based on CPIC guidelines; Other: Preemptive pharmacogenetic fluvastatin dose ...
Source: ClinicalTrials.gov - February 16, 2024 Category: Research Source Type: clinical trials
Prophylactic Treatment With Atorvastatin for Episodic Migraine.
Conditions: Episodic Migraine Interventions: Drug: Atorvastatin 40mg; Drug: Placebo; Drug: Atorvastatin 20mg Sponsors: St. Olavs Hospital; Haukeland University Hospital; Oslo University Hospital; University Hospital of North Norway; University Hospital, Akershus; Ullevaal University Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
